… into other forms of genetic blindness Validate and expand Axiomer ® : Further validate and expand ProQR's proprietary Axiomer ® RNA editing platform through first development … QR-1123, QR-421a, QR-411a, QR-504, the potential of our Axiomer ® editing platform, our plans and timing of …
… into clinical development and further advance our novel Axiomer ® RNA editing platform. With these events we look … or halt corneal degeneration in patients with FECD3. About Axiomer ProQR is pioneering a next-generation RNA technology called Axiomer ® , which could potentially yield a new class of …
Divestment of sepofarsen and ultevursen completed – Théa to continue development of sepofarsen and ultevursen for patients with LCA10 and Usher syndrome